SAB Biotherapeutics Inc. (SABS), a clinical-stage biopharmaceutical company, on Tuesday announced positive topline data from its Phase 1 trial of SAB-142, a potential disease-modifying therapy for Type 1 Diabetes.
The trial, conducted among healthy volunteers, met its primary objectives related to safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics.
SAB-142, a human anti-thymocyte immunoglobulin or hIgG, demonstrated a favorable safety profile with no reports of serum sickness or anti-drug antibodies at the target dose.
The drug also showed sustained immunomodulation and a mechanism of action analogous to rabbit ATG, suggesting significant potential in delaying or preventing the progression of T1D.
SAB Biotherapeutics plans to advance SAB-142 into Phase 2b clinical trials in 2025, focusing on adult and pediatric patients with new-onset Type 1 Diabetes.
The company will present full details of these promising results during an R&D webinar today, January 28, 2025, at 8:00 a.m. ET.As of September 30, 2024, SAB had cash, cash equivalents, and available-for-sale securities of $30.4 million.
The company expects that additional funds from the exercise of outstanding Tranche B warrants will provide sufficient cash to support its operations through 2026.
SABS closed Monday's (Jan.27 2025) trading at $4.36 up 6.34%. In premarket trading Tuesday, the stock is down 22.01% at $3.40.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.